The field of bispecific antibodies is advancing rapidly with results demonstrating their effective use in immunotherapy and oncology, as well as applications that are emerging in ophthalmology, infectious disease, and inflammation. This conference will highlight novel engineering approaches to bispecific antibody constructs and reveal key elements for efficacy and drug-like properties. The latest improvements in manufacturing, purification, stability, enhanced targeting, modulating immune response, expression, characterization, humanization and clearance will be shared.


Enhancing Function CrossMAb Vh-Vl and Fab

Jörg T. Regula, Ph.D., Head, Protein Analytics, Roche Diagnostics GmbH Roche

Multimerization Strategy to Enhance Potency and Developability of Bispecific Antibodies

Mahiuddin Ahmed, Ph.D., Assistant Attending for Immunotherapies, Pediatrics, Memorial Sloan Kettering Cancer Center

Bispecific FynomAbs with Tailored Architecture and Novel Modes-of-Action

Simon Brack, Ph.D., Director, Discovery Research, Discovery Research, Covagen (one of the Janssen pharmaceutical companies of Johnson & Johnson)

How to Minimalize Antibodies: The Success of Antibodies as Pharmaceuticals Has Triggered Interest in Crafting Much Smaller Mimics

Patrick J. McEnaney, Ph.D., Postdoctoral Researcher, Departments of Cancer Biology and Chemistry, The Scripps Research Institute Florida

Engineering Next-Generation Biotherapeutics: Developability & Manufacturability

Maria Wendt, Ph.D., Head, Science, Genedata


Arming of Effector T Cells or Tregs with BiTEs or CARs

Michael P. Bachmann, Ph.D., Professor, Helmholtz Zentrum Dresden Rossendorf (HZDR); Institute of Radiopharmaceutical Cancer Research, Radio-/Tumorimmunology

Developing Full-Length CD3 Bispecific Antibodies: From Bench to NHP

Javier Chaparro-Riggers, Ph.D., Director, Antibody Technology, Rinat Pfizer, Inc.

(scFab)2-Fc Type Bispecific Antibodies Engaging T Cells for Cancer Immunotherapy

Hyung-Kwon (Harry) Lim, Ph.D., Senior Research Scientist, Antibody Engineering, MOGAM Biotechnology Institute

A Bispecific Antibody Targeting CD47 and CD20 Selectively Binds and Eliminates Dual Antigen Expressing Lymphoma Cells

Jie Liu, M.D., Ph.D., Senior Scientist, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University

Title to be Announced

Hari Hariharan, Ph.D., Senior Director, Biotherapeutics Drug Discovery & Tech Development, Celgene Corp.


A Tale of Two Bacteria…Developing Bispecific Antibody Drugs for Pseudomonas aeruginosa and Clostridium difficile

G. Jonah Rainey, Ph.D., Senior Scientist, ADPE, MedImmune, LLC

Bispecific Antibodies Perform a Disappearing Act

Katherine Cygnar, Ph.D., Staff Scientist, Genome Engineering Technologies, Regeneron Pharmaceuticals, Inc.

Bispecific Antibody for Non-Oncology Disease Area Focusing on Hemophilia, a Bispecific Antibody

Shinya Ishii, Ph.D., Research Scientist, Discovery Research Dept, Chugai Pharmaceutical Co., Ltd.

For more details on the conference, please contact:

For partnering and sponsorship information, please contact:

Christina Lingham
Executive Director, Conferences
Phone: 781-972-5464

Jason Gerardi
(Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452

Carol Dinerstein
(Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781.972.5471